Rajkumar SV, Kumar S (2016) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101–119. https://doi.org/10.1016/j.mayocp.2015.11.007
Article
PubMed
Google Scholar
Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2017) Krebs in Deutschland 2013/2014. Häufigkeiten und Trends, 11. Ausgabe. Robert Koch-Institut, Berlin
Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8:479–491. https://doi.org/10.1038/nrclinonc.2011.63
CAS
Article
PubMed
PubMed Central
Google Scholar
Palumbo A, Anderson K (2011) Multiple Myeloma. N Engl J Med 364:1046–1060. https://doi.org/10.1056/NEJMra1011442
CAS
Article
PubMed
Google Scholar
Kuhr K, Wirth D, Srivastava K, Lehmacher W, Hellmich M (2016) First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. Eur J Clin Pharmacol 72:257–265. https://doi.org/10.1007/s00228-015-1998-5
CAS
Article
PubMed
Google Scholar
Harousseau J-L, Dreyling M, On behalf of the ESMO Guidelines Working Group (2010) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v155–v157. https://doi.org/10.1093/annonc/mdq178
Article
PubMed
Google Scholar
Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N, on behalf of the TLN Study Group (2014) Treatment of non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany—data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncol Res Treat 37:635–644. https://doi.org/10.1159/000368315
CAS
Article
PubMed
Google Scholar
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group.(2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37 . doi: https://doi.org/10.1016/S1470-2045(09)70284-0
CAS
Article
PubMed
Google Scholar
Khan RZ, Badros A (2012) Role of carfilzomib in the treatment of multiple myeloma. Expert Rev Hematol 5:361–372. https://doi.org/10.1586/ehm.12.26
CAS
Article
PubMed
Google Scholar
Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S (2015) The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol 11:1153–1168. https://doi.org/10.2217/fon.15.9
CAS
Article
PubMed
Google Scholar
Faiman B, Richards T (2014) Innovative agents in multiple myeloma. J Adv Pract Oncol 5:193–202
PubMed
PubMed Central
Google Scholar
Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331–2337. https://doi.org/10.1182/blood-2013-01-481325
CAS
Article
PubMed
Google Scholar
Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175:66–76. https://doi.org/10.1111/bjh.14193
Article
PubMed
Google Scholar
Mateos M-V, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R, San Miguel JF (2015) Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev 29:387–403. https://doi.org/10.1016/j.blre.2015.06.001
CAS
Article
PubMed
Google Scholar
Heng DYC, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, MacKenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149–154. https://doi.org/10.1093/annonc/mdt492
CAS
Article
PubMed
PubMed Central
Google Scholar
Marschner N, Staehler M, Müller L, Nusch A, Harde J, Koska M, Jänicke M, Goebell PJ, RCC Registry Group.(2017) Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials-analyses from the German Clinical RCC Registry. Clin Genitourin Cancer 15:e209–e215 . doi: https://doi.org/10.1016/j.clgc.2016.08.022
Article
PubMed
Google Scholar
Marschner N, Kaiser-Osterhues A (2017) Die Bedeutung von klinischen Tumorregistern. Im Focus Onkol 20:42–44. https://doi.org/10.1007/s15015-017-3513-6
Article
Google Scholar
Bergin K, McQuilten Z, Moore E et al (2017) Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk 17:133–144.e1. https://doi.org/10.1016/j.clml.2016.12.002
Article
PubMed
Google Scholar
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
CAS
Article
PubMed
Google Scholar
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682. https://doi.org/10.1093/aje/kwq433
Article
PubMed
Google Scholar
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol 31:448–455. https://doi.org/10.1200/JCO.2012.41.6180
CAS
Article
Google Scholar
Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST Trial. J Clin Oncol Off J Am Soc Clin Oncol 34:3609–3617. https://doi.org/10.1200/JCO.2016.66.7295
CAS
Article
Google Scholar
Mol L, Koopman M, van Gils CWM, Ottevanger PB, Punt CJA (2013) Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 52:950–955. https://doi.org/10.3109/0284186X.2013.777158
Article
PubMed
Google Scholar
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12:423–432. https://doi.org/10.1016/j.clml.2012.06.008
Article
PubMed
Google Scholar
Ludwig H, Durie BGM, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 111:4039–4047. https://doi.org/10.1182/blood-2007-03-081018
CAS
Article
PubMed
PubMed Central
Google Scholar
Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, Miguel JS, Sonneveld P, Palumbo A (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 98:980–987. https://doi.org/10.3324/haematol.2012.075051
Article
PubMed
PubMed Central
Google Scholar
Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wäsch R, Engelhardt M (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35. https://doi.org/10.1038/bcj.2011.34
CAS
Article
PubMed
PubMed Central
Google Scholar
Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R (2017) A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102:910–921. https://doi.org/10.3324/haematol.2016.162693
Article
PubMed
PubMed Central
Google Scholar
Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BGM, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125:2068–2074. https://doi.org/10.1182/blood-2014-12-615187
CAS
Article
PubMed
PubMed Central
Google Scholar
Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pegourie B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P (2013) Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 98:87–94. https://doi.org/10.3324/haematol.2012.067058
CAS
Article
PubMed
PubMed Central
Google Scholar
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators.(2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917 . doi: https://doi.org/10.1056/NEJMoa0801479
CAS
Article
PubMed
Google Scholar
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J (2015) Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 33:3921–3929. https://doi.org/10.1200/JCO.2014.58.7618
CAS
Article
PubMed
Google Scholar